15-Year Follow-Up begins for myeloma cell therapy patients

NCT ID NCT03741127

Ongoing Disease control Sponsor: Poseida Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows about 100 people with multiple myeloma who previously received an experimental cell therapy called P-BCMA-101. Researchers will monitor them for up to 15 years to see how safe and effective the treatment remains over time. A safety switch drug called rimiducid may also be given if needed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: P-BCMA-101 (a type of cell therapy) and rimiducid (a safety switch activator)
What this could lead to: If successful, this could show that P-BCMA-101 provides lasting control of multiple myeloma with manageable long-term side effects.
What could go wrong: This is an early-phase follow-up study, not a large trial. It may not prove long-term benefit, and risks like delayed side effects or loss of effectiveness remain possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Colorado Blood Cancer Institute

Denver, Colorado, 80218, United States
Johns Hopkins University

Baltimore, Maryland, 21205, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Sarah Cannon Research Institute at Tennessee Oncology

Nashville, Tennessee, 37203, United States
University of California Davis

Davis, California, 95618, United States
University of California San Francisco

San Francisco, California, 94143, United States
University of California, San Diego

San Diego, California, 92121, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of Kansas Cancer Center

Westwood, Kansas, 66205, United States
University of Maryland Greenebaum Comprehensive Cancer Center

Baltimore, Maryland, 21201, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Vanderbilt University Medical Center

Nashville, Tennessee, 37203, United States
Wayne State - Karmanos Cancer Institute

Detroit, Michigan, 48201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.